Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900640 | 0.85 | DRD3 (0.46) | DRD3GAACASP3MAPTRECQL | |
| SCHEMBL10871583 | 0.82 | DRD3 (0.44) | DRD3ALDH1A1CA12CA9 | |
| SCHEMBL8059312 | 0.80 | DRD3 (0.39) | DRD3GAACASP3MAPTRECQL | |
| SCHEMBL5069988 | 0.80 | NR1H2 (0.44) | DRD3MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5340450 | 0.80 | POLB (0.46) | DRD3GAACASP3MAPTRECQL | |
| SCHEMBL7484938 | 0.80 | DRD3 (0.41) | DRD3GAACASP3MAPTRECQL | |
| SCHEMBL2683476 | 0.80 | CASP3 (0.42) | DRD3GAACASP3ALDH1A1MEN1 | |
| SCHEMBL6302393 | 0.77 | CASP3 (0.43) | DRD3CASP3MAPTRECQLALDH1A1 | |
| SCHEMBL6357561 | 0.74 | DRD3 (0.51) | DRD3GAAALDH1A1CA12CA9 | |
| SCHEMBL29016393 | 0.72 | DRD3 (0.39) | DRD3MAPTALDH1A1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8716529-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-7582771-B2 | Process for the synthesis of cPLA2 inhibitors | WYETH (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20050049296-A1 | Process for the synthesis of cPLA2 inhibitors | WYETH (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | DRD3 69/4885GAA 597/4885CASP3 847/4885 |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | DRD3 69/4885GAA 597/4885CASP3 847/4885 |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | DRD3 69/4885GAA 597/4885CASP3 847/4885 |
| US-20050049296-A1 | Process for the synthesis of cPLA2 inhibitors | PLA2G12A, ACOX3, CPA2 | DRD3 2371/4885GAA 2017/4885CASP3 1428/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | DRD3 69/4885GAA 597/4885CASP3 847/4885 |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | DRD3 69/4885GAA 597/4885CASP3 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.